Global Herpes Market 2014-2018


◆タイトル:Global Herpes Market 2014-2018
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Herpes
Generally, herpes covers two different diseases: oral herpes, also known as cold sores and genital herpes. While oral herpes affects the area around the mouth, genital herpes affects area around the genitals. The HSV-1 causes oral herpes; both HSV-1 and HSV-2 cause genital herpes. HSV is a contagious virus that spread through contact. At present, there is no cure for herpes, however, treatments can help reduce the pain and decrease healing period.

TechNavio’s analysts forecast the Global Herpes market to grow at a CAGR of 10.14 percent over the period 2013-2018.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Herpes market for the period 2013–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs and vaccines used in the treatment and prevention of herpes simplex, herpes zoster and CMV infections that are available in the market.
The report also presents the vendor landscape and a corresponding detailed analysis of the vendors in the Global Herpes market. In addition, the report discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors and the market.

[Key Regions]
• Americas

[Key Vendors]
• Gilead Sciences
• Merck
• Novartis

[Other Prominent Vendors]
• Agenus
• AiCuris
• aRigen Pharmaceuticals
• Astellas Pharma
• CytoGenix
• Epiphany Biosciences
• F. Hoffmann-La Roche
• Genocea Biosciences
• NanoBio

[Market Driver]
• Significant Unmet Needs
• For a full, detailed list, view our report

[Market Challenge]
• Increasing Generic Competition
• For a full, detailed list, view our report

[Market Trend]
• Promising New Launches
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology


06.Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast

07.Competitive Assessment of Marketed Products
07.1 Five Forces Analysis

08.Rate of Incidence and Prevalence
08.1.1 US
08.1.2 UK

09.Diagnosis of Herpes

10.Market Segmentation by Product Type

11.Market Segmentation by Type of Virus

12.Market Assessment of Top Drugs
12.1 Zovirax
12.1.1 Sales
12.2 Valtrex
12.2.1 Sales

13.Geographical Segmentation

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.3 Other Prominent Vendors

22.Key Vendor Analysis
22.1 Gilead Sciences
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Geographical Segmentation by Revenue 2013
22.1.4 Recent Developments
22.1.5 SWOT Analysis
22.2 GlaxoSmithKline
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Sales by Geography
22.2.6 Pipeline Products
22.2.7 Business Strategy
22.2.8 Key Information
22.2.9 SWOT Analysis
22.3 Merck & Co. Inc.
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue 2013
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Developments
22.3.8 SWOT Analysis
22.4 Novartis
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Global Herpes Market 2013-2018 (US$ billion)
Exhibit 3: Diagnosis of Herpes
Exhibit 4: Global Herpes Market Segmentation by Type
Exhibit 5: GSK’s Zovirax Revenue 2010-2013 (US$ million)
Exhibit 6: GSK’s Valtrex Revenue 2010-2013 (US$ million)
Exhibit 7: Global Herpes Market by Geographical Segmentation 2013
Exhibit 8: Gilead Sciences: Geographical Segmentation by Revenue 2013
Exhibit 9: GlaxoSmithKline: Business Segmentation 2013
Exhibit 10: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 11: GlaxoSmithKline: Sales by Geography 2013
Exhibit 12: GlaxoSmithKline: Pipeline Products 2013
Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 14: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 15: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 16: Novartis: Business Segmentation by Revenue 2013
Exhibit 17: Novartis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 18: Novartis: Sales by Geography 2013


Gilead Sciences , GSK , Merck , Novartis , Agenus , AiCuris , aRigen Pharmaceuticals, Astellas Pharma, CytoGenix, Epiphany Biosciences, F. Hoffmann-La Roche, Genocea Biosciences, NanoBio





★調査レポート[ヘルペス治療薬の世界市場:口唇ヘルペス、陰部ヘルペス] (Global Herpes Market 2014-2018 / IRTNTR4662)販売に関する免責事項
[ヘルペス治療薬の世界市場:口唇ヘルペス、陰部ヘルペス] (Global Herpes Market 2014-2018 / IRTNTR4662)についてEメールでお問い合わせ